Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first
OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration …

Oncolytic viruses (OVs) constitute a new and promising immunotherapeutic approach
toward cancer treatment. This therapy takes advantage of the natural propensity of most …

During the past decades, anticancer immunotherapy has evolved from a promising
therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now …

This review provides an overview of recent developments in “chemical virology.” Viruses, as
materials, provide unique nanoscale scaffolds that have relevance in chemical biology and …

A number of human diseases stem from defective genes. One approach to treating such
diseases is to replace, or override, the defective genes with normal genes, an approach …

Leveraging the immune system to thwart cancer is not a novel strategy and has been
explored via cancer vaccines and use of immunomodulators like interferons. However, it …

In the past 5 years, the field of oncolytic virus research has matured significantly and is
moving past the stage of being a laboratory novelty into a new era of preclinical and clinical …

This review describes recent changes and progress in the field of polymer bioconjugation (ie
covalent attachment of synthetic polymers to biological entities such as nucleic acids …

Virotherapy is currently undergoing a renaissance, based on our improved understanding of
virus biology and genetics and our better knowledge of many different types of cancer …

The transfer of genes into cells, both in vitro and in vivo, is critical for studying gene function
and conducting gene therapy. Methods that utilize viral and nonviral vectors, as well as …